NAFLD
Conditions
Brief summary
Currently researches are focusing on the effect of antioxidants in the treatment of non-alcoholic fatty liver disease (NAFLD). Since N-acetyl cysteine (NAC) has been proven to have antioxidant and anti-inflammatory properties, therefore, we will conduct this study to determine the effect of NAC in patients of NAFLD with raised liver enzymes.
Detailed description
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing globally, and presents a challenge for the medical community since it has no FDA approved treatment. An important feature of non-alcoholic fatty liver disease (NAFLD) is hepatic steatosis leading to hepatic dysfunction . It has been reported that NAFLD patients with increased liver enzymes have a greater risk of developing complications like cirrhosis and end-stage liver disease. since N-acetyl cysteine (NAC) has been proven to have antioxidant and anti-inflammatory properties, therefore, we will conduct this study to determine the effect of NAC in patients of NAFLD with raised liver enzymes (ALT, AST). Patients presenting with ultrasound showing fatty liver with raised liver enzymes will be recruited. They will be randomized into two groups (group A and group B). The odd number patients will be allocated group A and even number patients will be allocated to group B. Group A: patients in this group will be advised to follow a diet plan & daily 20 minutes brisk walking. Group B: Patients in this group will be given NAC 200mg BD along with diet plan & exercise. This drug will be provided to the patients by the investigators free of cost. The liver function tests and side effects of NAC will be followed at 12 weeks .
Interventions
BEHAVIORALDiet and exercise
diet and exercise in patients of NAFLD
DRUGNAC with diet and exercise
NAC with diet and exercise in patients of NAFLD
Sponsors
Dow University of Health Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* • Patients of both genders between the ages of 20 years and 60 years, giving consent to be included in the study. * Patients having fatty liver on ultrasound with raised ALT and AST levels
Exclusion criteria
* • Patients having other causes of steatosis eg, excessive alcohol consumption, * Patients taking steatogenic medications such as, methotrexate , corticosteroids etc. * Patients suffering from other diseases that could increase ALT levels eg. Viral hepatitis, HIV, autoimmune liver diseases, infiltrative liver diseases. * Patients suffering from malignancies. * Patients who are not compliant to the medicine. * Pregnant and nursing females
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Alanine transaminase,aspartate aminotransferase | 12 weeks | Change in Alanine transaminase,aspartate aminotransferase |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Side Effects of NAC | 12 weeks | Side Effects of NAC |
Outcome results
None listed